Introduction
============

Mammographic density (MD) is the radiodense or white area on a mammogram. MD reflects the amount of fibrous stroma and epithelium in the breast \[[@B1],[@B2]\]. MD has been associated with stromal growth factors \[[@B3]\], as well as the number of epithelial cells, but not with increased epithelial cell proliferation \[[@B4]\].

MD is one of the strongest known breast cancer risk factors \[[@B5]\]. Women with MD of 75% or greater have a risk of breast cancer that is four to five times higher than women of the same age with little or no density (≤ 5%) \[[@B6]\].

Several studies have suggested that MD is at least partially inherited. Studies of twins suggest that genetic factors explain 30 to 60% of the variation in MD \[[@B7]-[@B9]\]. A number of studies have assessed the role of genetic variants identified through genome-wide association studies (GWAS) of breast cancer on MD \[[@B10],[@B11]\], but the results of these studies are inconsistent. A recent meta-analysis of GWAS on MD identified one variant (rs10995190) in the *zinc finger protein 365*gene (*ZNF365*) \[[@B12]\], but this variant only explained about 0.5% of the variance in MD. Thus, a large proportion of the variation is yet to be explained.

MD decreases with older age and menopause \[[@B13]\], and increases in postmenopausal women randomized to hormone treatment \[[@B14]\]. Parity \[[@B15]\] and early age at first full-term pregnancy are both associated with reduced MD \[[@B16]\]. Because of the clear role of hormones on MD, it has been suggested that genes involved in pathways that regulate steroid hormone synthesis and metabolism, hormone receptors, or genes in growth factor pathways may play a role. However, genetic association studies of candidate pathways either involving hormones or growth factors, have been few so far \[[@B17],[@B18]\]. Many studies have focused on selected variants, and these have not yielded consistent results \[[@B19]-[@B28]\]. It seems likely that such variants could determine how women metabolize hormone therapy (HT), or determine the downstream effect of hormones, and therefore some variants would only be important in women taking HT. Few of the studies so far have examined this association according to HT status \[[@B18],[@B21]\].

Therefore, we decided to investigate which genetic variants were the most important in explaining MD in HT users, and whether the association between genetic variants and MD was modified statistically by HT use. We evaluated the association between MD and 340 single nucleotide polymorphisms (SNPs) from about 30 putative genes in hormone metabolism and growth factor pathways.

Materials and methods
=====================

Participants
------------

Characteristics of the study participants and details about the study have previously been described \[[@B29]-[@B31]\]. Women selected for the study had attended the Norwegian Breast Cancer Screening Program (NBCSP) at least once. This national screening program invites all women aged 50 to 69 years to undergo a mammographic examination every two years. The attendance rate is 76.2% \[[@B32]\].

A questionnaire on various breast cancer risk factors, enclosed within the NBCSP invitation, was sent to a random sample of 17,050 women living in the counties of Oslo, Akershus and Hordaland in 2004. Menstrual and reproductive history, use of oral contraceptive and menopausal hormonal therapy, family history of breast cancer, current weight and height were assessed by the standardized questionnaire. A total of 12,056 (71%) of the invited women attended the screening program and 7,941 (66%) returned a completed questionnaire.

A subset (7,174) of the 7,941 women who had completed the health questionnaire was asked to complete a food frequency questionnaire and to provide us with two buccal swabs. Of these, 3,484 women (49%) returned the dietary questionnaire and 3,728 returned buccal swabs. We requested mammograms from the various radiological facilities and we focused the requests on mammograms from women who had completed a food frequency questionnaire and had had a screen film mammography in 2004. About 300 women from Oslo had undergone digital mammography. These women were not included in the current study as assessments from digital images tend to yield somewhat low percent MD compared with digitized screen film mammograms.

We obtained information on HT use and analog screening mammograms from the year 2004 on 2,876 women. Of these, 124 women were excluded for the following reasons; 17 women had had a previous cancer (12 = breast, 5 = ovarian), the breast area could not be determined on mammograms from 3 women, 28 had incomplete data on age, and 73 incomplete data on body mass index (BMI) (height = 46/weight = 67). Three women were excluded because they used progesterone-only HT. After the exclusions, a total of 2,752 women with mammograms and HT data were left for analysis. All the participants signed an informed consent and the study was approved by the Regional Ethics Committee and the Norwegian Data Inspectorate.

Mammographic density analysis
-----------------------------

Mammograms (left craniocaudal) were scanned using a high-resolution Kodak Lumisys 85 scanner with automatic feeder (Kodak, Rochester, NY, USA). Computer-assisted readings of absolute areas of dense and non-dense tissues, as well as percent density, were performed using the Madena software \[[@B33]\]. This method provides a continuous measure of density and a separate estimate of the absolute areas of dense and non-dense tissues. Only analog mammograms were included due to concern that the digitally obtained images would not yield comparable density readings. The density assessments were performed by an experienced reader (G.U.), whereas a research assistant trained by G.U. conducted the breast area measurements. Both readers were blinded to all subject characteristics. Percent MD was calculated by dividing the absolute breast density by the total breast area and multiplying it by 100. Some suggest that absolute density is the optimal method \[[@B34]\], but the majority of the studies on MD have used percent density \[[@B6]\], and we therefore limited these results to percent MD.

DNA collection and extraction
-----------------------------

Three thousand seven hundred and twenty-eight (3,728) women returned buccal swabs out of which 3,317 were genotyped. Of these, 241 women had to be excluded due to a sample call rate \< 80%, yielding 3,076 women. Of these, we had risk factor information and mammograms collected in 2004 on 2,397 women. DNA was extracted from buccal swabs using standard modified protocol for the QIAamp DNA blood kit (Qiagen, Valencia, CA, USA).

Selection of SNPs
-----------------

For *AR*, *COMT*, *CYP1A1/CYP1A2*, *CYB1B1*, *ESR2*, *HSD17B1*, *IGFBP1/IGFBP3*, *IL6*, *PGR*, *PPARG*, *PRL*, *SULT1A1/SULT1A2*, *SULT1E1*, *TGFB1*, *TNF*and *VEGF*, we selected tag SNPs to capture the genetic variation in each gene. We selected linkage disequilibrium tagging SNPs across each gene, from 20 kb upstream of 5\' untranslated region (UTR) to 10 kb downstream of the 3\' UTR. Because this study shared an analysis platform with a study of Chinese women, HapMap Caucasians of European descent (CEU) data (release 24) \[[@B35]\] and HapMap Han Chinese in Beijing (CHB) data (release 24), as well as the Snagger \[[@B36]\] or modified Tagger approach were used to capture all common SNPs (minor allele frequency ≥ 5%) in Caucasians or Chinese with minimum pair wise r^2^\> 0.8. For, *ADH1C*, *AKR1C4*, *CSHL1*, *CYP17A1*, *CYP19A1*, *ESR1*, *FGFR2*, *GHRHR*, *HCV3289988*, *HSD3B1/HSD3B2*, *POU5F1*, *PRLR*, *SHBG*and *SRD5A2*, we selected one or a few SNP(s) of interest for each gene (Table [2](#T2){ref-type="table"}).

###### 

List of genes on single nucleotide polymorphisms (SNPs) genotyped and tagging SNP approach.

  Genes             Number of SNPs successfully genotyped for each gene   Tagging SNP approach
  ----------------- ----------------------------------------------------- ----------------------
  ADH1C             1                                                     No
  AKR1C4            1                                                     No
  CSHL1             1                                                     No
  CYP17A1           1                                                     No
  CYP19A1           2                                                     No
  ESR1              12                                                    No
  FGFR2             1                                                     No
  GHRHR             1                                                     No
  HCV3289988        1                                                     No
  HSD3B1/HSD3B2     3                                                     No
  POU5F1            1                                                     No
  PRLR              3                                                     No
  SHBG              13                                                    No
  SRD5A2            1                                                     No
                                                                          
  AR                6                                                     Yes
  COMT              29                                                    Yes
  CYP1A1/CYP1A2     13                                                    Yes
  CYP1B1            17                                                    Yes
  ESR2              29                                                    Yes
  HSD17B1           3                                                     Yes
  IGFBP1/IGFBP3     29                                                    Yes
  IL6               19                                                    Yes
  PGR               32                                                    Yes
  PPARG             32                                                    Yes
  PRL               34                                                    Yes
  SULT1A1/SULT1A2   5                                                     Yes
  SULT1E1           1                                                     Yes
  TGFB1             11                                                    Yes
  TNF               15                                                    Yes
  VEGF              21                                                    Yes

\*See methods for details on how tagging SNPs were selected.

Genotyping of SNPs
------------------

Genotyping was done using an Illumina BeadLab System (Illumina Inc., San Diego, CA, USA) and GoldenGate™ Genotyping technology in the University of Southern California Genomics Center. Samples were run in a 96-well format using Illumina Sentrix Array technology on a BeadArray Reader. BeadStudio Software (version 3.0.9) with Genotyping Module (version 3.0.27) (Illumina) was used for analyzing scanned samples. The SNPs with \< 85% call rates were excluded: this resulted in the exclusion of 4% of SNPs. The genotyping concordance rate based on 41 duplicate samples was 84%. Out of 340 SNPs in the hormone metabolism and growth factor pathways, 18 SNPs departed from Hardy-Weinberg equilibrium (HWE) (*P*\< 0.001), leaving 322 SNPs for further analysis. None of these excluded 18 SNPs were associated with MD regardless of the hormone use status (data not shown).

Menopausal status and HT use
----------------------------

The classification of postmenopausal women was limited by our questionnaire where women were asked if they had undergone a) complete cessation of menstruation of at least six months b) previous bilateral oophorectomy c) hysterectomy without bilateral oophorectomy d) used HT before menopause. Out of the 2,397 women, we excluded 342 pre- and perimenopausal women. We also excluded 19 women who had undergone simple hysterectomy without bilateral oophorectomy since these women could not be classified on menopausal status. Our final sample size was 2,036 postmenopausal women. Excluding women with menopause within the past year (*N*= 177) yielded essentially unchanged results, and did not alter the order of the most important SNPs (results not shown). We therefore present analyses using the six month definition of menopause.

HT use was assessed by asking two questions about 1) ever use of HT with a proposed list of HT preparations and 2) current use of HT. If a woman had used the specified HT for more than three months at the time of completing the questionnaire, she was considered a current user. A woman could have used both estrogen-only (ET) and combined estrogen and progestin therapies (EPT) in her lifetime, but only one of these currently. Current EPT users were subdivided further into norethisterone acetate (NETA) regimen users or non-NETA users.

Statistical analyses
--------------------

We used multivariate linear regression to examine the relation between percentage MD and SNPs. The MD variable was treated in a continuous manner, without any transformations, as the model\'s residuals satisfied the normality and homoscedasticity assumptions. We adjusted all analyses for age at screening (continuous) and BMI (kg/m^2^, continuous).

We ran these analyses on both additive and dominant models. However, because the results were largely similar between the two genetic models, and few women were homozygote for the variants of many SNPs, we only present the dominant model (results available upon request). We conducted analyses, with and without Bonferroni adjustments for multiple comparisons (the number of SNPs per gene) within each stratum defined by hormone use. We also ran a test for heterogeneity between HT users and non-users and present the *P*values for this interaction (*P*~int~). In the results section, we specifically comment on results where the stratum-specific two-sided *P*values are less than 0.01 and the Bonferroni-adjusted *P*values (Pb) are less than 0.05.

We estimated least squares means (marginal means) on MD and all our explanatory variables among never, current and past EPT users. Least squares means are the group mean after having controlled for a covariate (age and BMI). We subdivided HT users into ET or EPT. EPT users were further subdivided into NETA users or non-users.

Results
=======

Characteristics of the study population by strata of EPT use (no, past and current) are shown in Table [1](#T1){ref-type="table"}. As previously described, MD was higher in current EPT users than in past or never users \[[@B31]\]. There were statistically significant differences in percent density, BMI and in age at screening between never, past and current EPT users. Table [2](#T2){ref-type="table"} shows the number of SNPs successfully genotyped for each gene we investigated.

###### 

Characteristics of no, past and current estrogen and progestin therapy (EPT) users (*N*= 2,036).

                                       No EPT (*N*= 1,176)   Past EPT (*N*= 612)   Current EPT (*N*= 248)                                             
  ------------------------------------ --------------------- --------------------- ------------------------ ----- ------- ------ ----- ------- ------ --------
  **Mammographic density (%)**         1,176                 17.07                 0.46                     612   18.99   0.45   248   23.34   0.51   0.0001
  **Age at screening (years)**         1,176                 58.19                 0.18                     612   59.22   0.15   248   57.33   0.15   0.0001
  **Body mass index (kg/m^2^)**        1,176                 25.44                 0.13                     612   24.91   0.10   248   24.15   0.11   0.0001
  **Age at menarche (years)**          1,169                 13.16                 0.04                     607   13.36   0.04   246   13.31   0.04   0.1025
  **Age at first pregnancy (years)**   1,049                 21.75                 0.25                     540   22.3    0.24   225   22.28   0.24   0.3602
  **Number of children**               1,114                 2                     0.03                     587   2       0.03   239   2       0.03   0.7252
  **Education (years)**                1,164                 12.75                 0.10                     605   13.01   0.10   245   12.85   0.10   0.2807

^1^Adjusted for age and BMI, ^2^standard error, ^3^analysis of variance.

Among all postmenopausal women, there was no association between SNPs and MD after Bonferroni adjustments (Table S1 in Additional file [1](#S1){ref-type="supplementary-material"}). Among postmenopausal never HT users, there was an association between MD and a variant in the *tumor necrosis factor*(*TNF*) gene (rs769177; Pb = 0.020), and with a variant in the *sulfotransferase*(*SULT1A1/SULT1A2*) gene (rs1968752; Pb = 0.035) (Table S2 in Additional file [2](#S2){ref-type="supplementary-material"}).

For postmenopausal current ET users (Table [3](#T3){ref-type="table"}) there was an association between a variant in the *cytochrome P450*(*CYP1B1*) gene (rs4670813, Pb = 0.0396) and MD. In current EPT users (Table [4](#T4){ref-type="table"}) a variant in the *prolactin*(*PRL*) gene (rs10946545, Pb *=*0.0144) was significantly associated with MD. The results from the analysis of all SNPs in all women combined, and in ET users and EPT users separately, as well as the interaction tests are shown in Table S3 in Additional file [3](#S3){ref-type="supplementary-material"}. Mean percent mammographic density was highest in homozygous wild-type carriers of *PRL*rs10946545 who currently used EPT (Figure [1](#F1){ref-type="fig"}).

###### 

Top twenty single nucleotide polymorphism (SNPs) in postmenopausal current estrogen-only users (*N*= 78) that showed the strongest heterogeneity between never hormone therapy users and estrogen-only users.

  Gene            SNP          SNPs per gene   Alleles   WW   WV+VV   Beta^1^   SE      P^1^     Pb^2^        Pint^3^
  --------------- ------------ --------------- --------- ---- ------- --------- ------- -------- ------------ ---------
  PPARG           rs1175543    32              A/G       42   36      -9.80     3.00    0.0017   0.0535       0.0028
  CYP1B1          rs4670813    17              G/A       25   53      -9.99     3.17    0.0023   **0.0396**   0.0059
  CYP1B1          rs162550     17              G/C       44   34      8.19      3.11    0.0103   0.1753       0.0068
  ESR2            rs1256063    29              G/A       65   13      12.27     4.00    0.0030   0.0868       0.0069
  IGFBP1/IGFBP3   rs1496497    29              G/A       47   31      -8.08     3.13    0.0119   0.3464       0.0155
  IL6             rs6949149    19              G/T       70   8       -12.82    4.97    0.0119   0.2256       0.0206
  TGFB1           rs8179181    11              A/T       48   30      7.91      3.16    0.0144   0.1579       0.0214
  ESR1            rs2295190    12              G/T       51   27      -6.45     3.36    0.0590   0.7086       0.0293
  PPARG           rs1151996    32              A/C       36   42      -7.18     3.11    0.0236   0.7554       0.0520
  CYP1B1          rs1625       17              T/G       49   29      6.74      3.25    0.0418   0.7098       0.0557
  TGFB1           rs1982072    11              A/T       35   43      -6.32     3.17    0.0498   0.5478       0.0577
  CYP1A1/CYP1A2   rs11072507   13              C/G       39   39      7.26      3.24    0.0281   0.3656       0.0578
  CYP1B1          rs162557     17              G/A       47   31      6.05      3.21    0.0635   1.0791       0.0622
  IGFBP1/IGFBP3   rs10241749   29              A/G       49   29      7.10      3.35    0.0375   1.0878       0.0657
  PPARG           rs2120825    32              T/G       56   22      8.12      3.42    0.0201   0.6421       0.0733
  COMT            rs12627876   29              C/T       77   1       26.61     13.83   0.0582   1.6881       0.0827
  CYP1A1/CYP1A2   rs2606345    13              A/C       38   40      7.00      3.09    0.0263   0.3415       0.0886
  IGFBP1/IGFBP3   rs4619       29              A/G       28   50      -6.51     3.31    0.0531   1.5400       0.0950
  HSD3B1/HSD3B2   rs6428828    3               A/T       38   40      5.77      3.08    0.0650   0.1951       0.0954
  PRL             rs1123886    34              T/C       36   42      6.22      3.17    0.0533   1.8109       0.2058

^1^From linear regression models using percent mammographic density as the outcome variable. Adjusted for age and BMI in a dominant model of inheritance. See Table S2 in Additional file [2](#S2){ref-type="supplementary-material"} for the stratum-specific results in never HT users. ^2^Bonferroni-adjusted *P*values. ^3^*P*for interaction for ET vs. never HT users in all postmenopausal women (*N*= 2,036).

###### 

Top twenty single nucleotide polymorphisms (SNPs) that showed the strongest heterogeneity in association between never hormone therapy users (*N*= 1,008) and postmenopausal current estrogen and progestin users (*N*= 248), by *P*for interaction.

  Gene            SNP          SNPs per gene   Alleles   WW    WV+VV   Beta    SE      P^1^     Pb^2^        Pint^3^
  --------------- ------------ --------------- --------- ----- ------- ------- ------- -------- ------------ ---------
  PRL             rs10946545   34              G/A       219   29      10.86   3.04    0.0004   **0.0144**   0.0008
  ESR2            rs12434245   29              C/T       216   32      -8.09   2.94    0.0063   0.1839       0.0034
  TNF             rs3093553    15              T/G       228   20      -9.86   3.63    0.0070   0.1050       0.0046
  CYP1A1/CYP1A2   rs3743       13              G/C       233   15      -9.79   4.16    0.0194   0.2524       0.0061
  TNF             rs3093662    15              A/G       225   23      -8.53   3.42    0.0133   0.2002       0.0064
  TNF             rs4947324    15              C/T       214   34      -8.53   2.89    0.0035   0.0520       0.0154
  PRL             rs2744117    34              G/T       212   36      7.97    2.80    0.0048   0.1633       0.0206
  ESR2            rs7159462    29              C/T       214   34      -6.61   2.87    0.0222   0.6447       0.0248
  PRL             rs1156546    34              A/C       163   85      4.77    2.09    0.0230   0.7812       0.0249
  SHBG            rs6258       13              C/T       246   2       23.25   11.09   0.0370   0.4815       0.0345
  ESR2            rs10137185   29              C/T       209   39      -5.20   2.73    0.0575   1.6684       0.0425
  PGR             rs569857     32              T/A       217   31      -5.69   3.02    0.0603   1.9306       0.0434
  PPARG           rs4279078    32              G/A       203   45      6.09    2.58    0.0190   0.6082       0.0442
  PPARG           rs2960420    32              C/G       111   137     -4.60   1.99    0.0219   0.6997       0.0458
  VEGF            rs699946     21              A/G       159   89      -3.96   2.08    0.0587   1.2333       0.0719
  PGR             rs7106686    32              G/A       188   60      -4.46   2.32    0.0559   1.7873       0.0854
  PRL             rs9358533    34              C/T       207   41      6.45    2.66    0.0159   0.5413       0.0927
  PGR             rs507141     32              G/A       185   63      4.40    2.28    0.0550   1.7594       0.1431
  PGR             rs5181       32              C/G       208   40      -5.58   2.72    0.0411   1.3164       0.1753
  PRL             rs1205960    34              C/T       140   108     -3.86   2.01    0.0559   1.8994       0.1765

^1^From linear regression models using percent mammographic density as the outcome variable. Adjusted for age and BMI in a dominant model of inheritance. ^2^Bonferroni-adjusted *P*values. ^3^*P*for interaction for EPT vs. never HT users in all postmenopausal women (*N*= 2,036).

![**Mean percent mammographic density by *prolactin*(*PRL*) rs10946545 genotype and hormone therapy use**. A figure that presents mean percent mammographic density by the *PRL*gene (rs10946545) in women with two wild-type alleles and with one or two variant (minor) alleles in never hormone therapy (HT) users and in current estrogen and progestin therapy (EPT) users.](bcr3337-1){#F1}

NETA is an EPT-based regimen common in Nordic countries. The results remained statistically significant when analyses were restricted to NETA users (results not shown).

When we adjusted for parity (parous/nulliparous), the three *PRL*SNPs that were significant in the EPT users remained statistically significant before Bonferroni correction (rs10946545 *P*= 0.0028/rs2744117 *P*= 0.0218/rs1156546 *P*= 0.0345). None of these were statistically significant after Bonferroni adjustment. In the interaction test between these three SNPs and EPT, two of the three SNPs remained statistically significant (rs10946545 *P*~int~= 0.0051/rs1156446 *P*~int~= 0.0317) after adjustment for parity.

Discussion
==========

In this study of postmenopausal Norwegian women, we found that MD was associated with several variants in growth factor and hormone metabolism genes *(PRL*, *CYP1B1*, *SULT1A1*/*SULT1A2*and *TNF*). However, different variants appeared to be important depending on the women\'s HT use.

There have been a number of studies of genetic variations and MD \[[@B18]-[@B28]\]. However, few studies have examined this association by HT use or tested the interaction with hormone use. Below, we discuss our results by subgroup of HT use.

Among postmenopausal never HT users (*N*= 1,008), we found associations between MD and variants in the *TNF*and the *SULT1A1/SULT1A2*genes. *TNF*refers to a group of cytokines that are important in inflammation, as well as in growth, differentiation and cell death. *TNF*has been implicated in tumor regression \[[@B37],[@B38]\], and there is some evidence that *TNF*genetic variants are associated with breast cancer risk \[[@B39]\]. Our findings are consistent with this. As far as we know, no other study has examined the association between *TNF*variants and MD. One cross-sectional study on postmenopausal American women found no statistically significant associations between circulating *TNF*levels and MD after adjustment for BMI \[[@B40]\]. However, the study did not take HT use into account. In our study, one *TNF*variant was important in never users and in all women, the latter association possibly because more than half of the women were never users. However, this variant was not important in EPT users, nor was the interaction between never users and EPT users statistically significant. Two other *TNF*variants showed statistical significance in the interaction between never users and EPT users, but not after Bonferroni adjustments. The exact role of *TNF*genetic variation on mammographic density is thus unclear, however, if inflammation is an important aspect of breast cancer development, then it seems reasonable that *TNF*variants may play a role.

Sulfotransferase 1A1 and 1A2 are enzymes that are encoded by the *SULT1A1*and *SULT1A2*genes. Sulfotransferase enzymes catalyze hormones, drugs and xenobiotic compounds \[[@B41]\]. In a review of 18 studies of SNPs located in genes of the estrogen pathway, *SULT1A1*/*SULT1A2*did not show any association with MD on the overall study population \[[@B42]\]. In a study on American premenopausal women, it was concluded that SNPs in *SULT1A1*locus may influence percent density \[[@B43]\]. In our study, *SULT1A1/SULT1A2*was important in never users, but not in HT users. A possible explanation could be that the *SULT*variants interact with exposures important for MD in women not using hormones, although it may also be a chance finding.

There were few current ET users in our study (*N*= 78), but among them we observed a negative association between MD and rs4670813 (*CYP1B1*). *CYP1B1*belongs to the cytochrome P450 super family of enzymes and is important in the metabolism of estrogen that may affect breast cancer risk. *CYP1B1*catalyzes formation of potentially carcinogenic catechol estrogens and forms 4-hydroxylation of estrone \[[@B44]\]. *CYP1B1*expression levels have also been reported to be lower in tumors than in adjacent benign tissue \[[@B45]\], suggesting that a key factor in breast carcinogenesis is not increased 4-hydroxylation but reduced estradiol metabolism. Thus, both increased and reduced *CYP1B1*activity has been hypothesized to be associated with breast cell proliferation. In the SWAN study, *CYP1B1*; rs162555 was associated with a higher MD in pre- and early perimenopausal women \[[@B27]\]. In a cross-sectional study on postmenopausal women who participated in two randomized, double-blind, placebo-controlled studies, there was no evidence of an association between MD and genotypes in women randomized to ET \[[@B21]\]. In a case-control study of American postmenopausal women (PACE), the authors found an association between *CYP1B1*; rs1056827 and breast cancer risk in ever EPT users \[[@B46]\]. As long as the functional role of rs4670813 is unknown, the mechanism behind our observed negative association between MD and rs4670813 remains elusive.

The most significant findings in our study were the association between a variant in *PRL*gene (rs10946545) and MD in current EPT users (*N*= 248) and in users of NETA-based EPT. Prolactin, also known as luteotropic hormone, is a protein that in humans is encoded by the *PRL*gene \[[@B47]\]. It is produced by the pituitary gland and in lesser amounts by several other tissues, including breast tissue. Prolactin plays an important role in breast development, differentiation and lactation \[[@B48]\], but may also have procarcinogenic effects \[[@B49],[@B50]\]. There are prolactin receptors in both normal breast tissue and in breast tumor tissue \[[@B51]-[@B53]\]. Our findings are consistent with the results in a case-control study on Polish women. In that study, two SNPs (rs7718468 and rs13436213) in the *prolactin receptor*(*PRLR*) gene were associated with breast cancer risk in postmenopausal women \[[@B54]\]. In our study, we found this association in current EPT users. Adjustments for parity did not obliterate the association, and the association was observed in strata of both parous and nulliparous women (results not shown). How parity and prolactin interact with hormones important for breast epithelial proliferation is not yet clear, but may be important in breast cancer development. Parity has previously been found to primarily reduce risk of estrogen receptor and progestin receptor positive (ER+PR+) cancer, while breastfeeding reduces risk of both ER+ PR+ and ER-PR- cancer \[[@B55]\]. Whether *PRL*plays a role in this interaction is unknown. When we adjusted for parity, the SNPs in the *PRL*gene remained statistically significant, suggesting that the number of children does not attenuate the association between variants in *PRL*and MD.

In a case-control study within the prospective Nurses\' Health Study, plasma level of prolactin was positively associated with the risk of breast cancer \[[@B56]\]. Data from a randomized, placebo-controlled study suggested that EPT use in postmenopausal women increased the *PRL*concentration \[[@B57]\]. However, that study did not examine the role of genetic variations. In the first family linkage study on MD, a locus on chromosome 5p was associated with MD, and the *PRLR*is at a region surrounding this locus \[[@B28]\]. Taken together, current data suggest that both *PRL*and *PRLR*may be important for MD.

Summing up, our results indicate that a number of genetic variants that determine how women metabolize HT, or how HT exerts its effect on the breast, might be associated with MD in HT users.

Strengths and weaknesses
------------------------

There are several strengths of this study. First, our study investigated the association between genetic variations in the hormone metabolism and growth factor pathways and MD in HT users and non-users, and in ET and EPT users. Not many other studies have investigated these relations. Another strength of this study is the sample size (*N*= 2,036), and that it is population based. A third strength is that we had risk factor information available, although we only used age at screening, height/weight, hormone use and parity in this analysis. A weakness of the study is that we were not able to identify a study with similar types of hormone users, and thus have not been able to replicate our findings in another study. Further validation is therefore important. Another weakness is that we had only information on current height and weight (2004). We obtained the mammograms from three different screening facilities with different equipment and personnel. Even though the mammography procedures are standardized within the NBCSP, there is variation between radiographers on how to position and compress the breasts. Nevertheless, these potential sources of errors are not likely to be associated with genotype and would be expected to give a bias toward the null. We did not perform longitudinal studies, nor studies to establish the functional consequences of the SNPs, thereby restricting the ability to assess causation. To adjust for multiple comparisons we used Bonferroni adjustment. This is rather conservative, and we may thus have failed to identify other stratum-specific estimates that are biologically relevant.

Conclusions
===========

We found some evidence that variants in the *PRL*gene were associated with MD in current EPT and NETA users. Variants in *TNF*and *SULT1A1/SULT1A2*were associated with MD in never HT users. These findings may suggest that several genes in the hormone metabolism/growth factor pathways are implicated in determining MD. Some genetic variants in combination with specific HT may increase MD in susceptible women. Exploring the functional role of the SNPs associated with MD will further clarify the biological mechanisms involved.
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